Author:
Kamble Ritu,Puranik Amita,Narvekar Aditya,Dandekar Prajakta,Jain Ratnesh
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference33 articles.
1. AndreaHawe; MichaelWiggenhorn; Marcovan de Weert; Joerg H.O.Garbe;, Hanns-christianMahler;, WimJiskoot, Forced Degradation of Therapeutic Proteins, J. Pharm. Sci. 101 (2011) 895–913. 10.1002/jps.22812.
2. European Medicines Agency, ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, n.d. https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnologicalbiological-products.
3. Forced degradation of recombinant monoclonal antibodies: a practical guide;Nowak;MAbs.,2017
4. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars;Kang;Anal. Bioanal. Chem.,2020
5. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes;Haberger;MAbs.,2014
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献